Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 27.5%
Concerns1
- Low return on equity of 2.0%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.04 K Cr | β | βΉ22.00 Cr | β | β | 1.1% | 25.0% | -8.3% |
| Mar 2024 | βΉ835.00 Cr | β | βΉ24.00 Cr | β | β | 2.0% | 39.6% | -25.0% |
| Mar 2023 | βΉ598.00 Cr | β | βΉ32.00 Cr | β | β | 5.7% | 65.2% | -3300.0% |
| Mar 2022 | βΉ362.00 Cr | β | βΉ-1.00 | β | β | -0.5% | 56.0% | -98.1% |
| Mar 2021 | βΉ232.00 Cr | β | βΉ-54.00 | β | β | -26.9% | -6.5% | 50.0% |
| Mar 2020 | βΉ248.00 Cr | β | βΉ-36.00 | β | β | -14.1% | 22.8% | 80.0% |
| Mar 2019 | βΉ202.00 Cr | β | βΉ-20.00 | β | β | -6.7% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,160 |
| Total Expenses | 886 |
| EBIT / Operating Profit | 274 |
| OPM % | 24% |
| Other Income | 52 |
| Finance Costs | 81 |
| Depreciation & Amortisation | 174 |
| Profit Before Tax | 71 |
| Tax % | - |
| Net Profit / PAT | 49 |
| EPS (βΉ) | 1.56 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Dr. Agarwal's Health Care Limitedthis co. | βΉ15.85 K Cr | βΉ1.04 K Cr | 302.00 | 8.09 | 62.83 | 25.0% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |